Lyell Immunopharma, Inc

Contributing Author

Recent Articles by Lyell Immunopharma, Inc

12 hours	Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer LYEL +13.54% GlobeNewswire
Feb-23	Lyell Immunopharma Announces Participation in March Investor Conferences LYEL +6.12% GlobeNewswire
Feb-12	Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma LYEL GlobeNewswire
Dec-07	Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition LYEL GlobeNewswire
Nov-12	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 LYEL GlobeNewswire
Nov-10	Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer LYEL GlobeNewswire
Nov-03	Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition LYEL GlobeNewswire
Sep-03	Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee LYEL GlobeNewswire
Sep-02	Lyell Immunopharma Announces Participation in September Investor Conferences LYEL GlobeNewswire
Aug-12	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 LYEL GlobeNewswire
Jul-25	Lyell Immunopharma Announces up to $100 Million Equity Private Placement LYEL +19.31% GlobeNewswire
Jun-23	Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series LYEL +6.62% LYEL GlobeNewswire
Jun-17	Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma LYEL GlobeNewswire
Jun-09	Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments LYEL -13.39% LYEL GlobeNewswire
Jun-04	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference LYEL +68.59% LYEL -14.92% GlobeNewswire
May-13	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 LYEL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)